跳至主要内容
临床试验/NCT01637025
NCT01637025已完成不适用

A Prospective, Randomized, Controlled Study to Evaluate the Safety and Effectiveness of Traumastem as an Adjunct to Hemostasis for Tissue Bleeding in Open Cardiac, Intra-abdominal (Including Retroperitoneal) and Pelvic Surgery

Baxter Healthcare Corporation24 个研究点 分布在 4 个国家目标入组 111 人开始时间: 2012年5月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
111
试验地点
24
主要终点
Occurrence of adverse events (AEs)/ adverse device effects (ADEs)

研究概览

简要总结

The purpose of this study is to evaluate the safety and effectiveness of Traumastem to help stop bleeding in participants undergoing open cardiac, intra-abdominal (including retroperitoneal) and pelvic surgery as compared to Surgicel® Original (Surgicel; in some countries marketed as Tabotamp®)

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Occurrence of adverse events (AEs)/ adverse device effects (ADEs)

时间窗: ≤30 ± 5 days/ end-of-study visit after device application

Occurrence of adverse events (AEs)/ adverse device effects (ADEs) up to 30 ± 5 days/ end-of-study visit after device application.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (24)

Loading locations...

相似试验